Discover recent clinical trial authorizations supported by human‑based in‑vitro models. This section highlights how developers use advanced in vitro systems to generate evidence that plays a central role in the safety and efficacy packages regulators accept as part of Investigational New Drug (IND) or Clinical Trial Application (CTA) submissions, enabling first‑in‑human studies, drug repurposing and other early‑stage clinical trials.